Agopton;Amarin;Aprazol;Bamalite;Biuret;Biuret Gr;Biuret Reagent;Biuret Reagent Solution;Blason;Compraz;Dakar;Ilsatec;Ketian;Lancid;Lanproton;Lansopep;Lansoprazol [INN-Spanish];Lansoprazole [Usan:Ban:Inn];Lansoprazolum [INN-Latin];Lanston;Lanz;Lanzol-30;Lanzopral;Lanzor;Lasoprol;Limpidex;Mesactol;Monolitum;Ogast;Ogastro;Opiren;Prevacid;Prevacid Iv;Prevacid Solutab;Prevpac;Prezal;Pro Ulco;Promp;Prosogan;Suprecid;Takepron;Ulpax;Zoprol;Zoton;

AG 1749;lansoprazole;

Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by TAP Pharmaceutical Products. Lansoprazole has been marketed for many years and is one of several PPI’s available.

• Matrix laboratories ltd
• Novartis consumer health inc
• Sandoz inc
• Takeda pharmaceuticals north america inc
• Teva pharmaceuticals usa

Synthesis Reference	Not Available
General Reference	Not Available

Form	Route	Strength
Capsule, delayed release	Oral
Tablet, delayed release	Oral

Unit description	Cost	Unit
Prevacid SoluTab 100 15 mg Dispersible Tablet Box	620.65 USD	box
Prevacid NapraPAC 84 15-500 mg Kit Box	175.8 USD	box
Prevpac Miscellaneous	32.02 USD	ea
Prevpac patient pack	28.22 USD	each
Lansoprazole 100% powder	27.54 USD	g
Prevacid iv 30 mg vial	27.31 USD	vial
Prevacid dr 15 mg capsule	6.25 USD	capsule
Prevacid SoluTab 30 mg Dispersible Tablet	6.21 USD	dispersible tablet
Prevacid 15 mg capsule dr	6.0 USD	capsule
Prevacid 30 mg capsule dr	6.0 USD	capsule
Prevacid dr 30 mg capsule	5.91 USD	capsule
Lansoprazole 15 mg Delayed Release Capsule	5.9 USD	capsule
Lansoprazole 30 mg Delayed Release Capsule	5.9 USD	capsule
Prevacid 15 mg solutab	5.73 USD	tablet
Prevacid 30 mg solutab	5.73 USD	tablet
Lansoprazole dr 15 mg capsule	5.67 USD	capsule
Lansoprazole dr 30 mg capsule	5.67 USD	capsule
Prevacid 30 mg Delayed Release Capsule	4.45 USD	capsule
Prevacid 15 mg Delayed Release Capsule	4.32 USD	capsule
Apo-Lansoprazole 15 mg Delayed Release Capsule	1.17 USD	capsule
Apo-Lansoprazole 30 mg Delayed Release Capsule	1.17 USD	capsule
Novo-Lansoprazole 15 mg Delayed Release Capsule	1.17 USD	capsule
Novo-Lansoprazole 30 mg Delayed Release Capsule	1.17 USD	capsule
Prevacid 24hr dr 15 mg capsule	0.86 USD	capsule

Type	small molecule

Classes

Benzimidazoles Ethers

Substructures

Benzimidazoles Pyridines and Derivatives Ethers Halogen Derivatives Benzene and Derivatives Imidazoles Heterocyclic compounds Aromatic compounds Imines Cyanamides Sulfoxides

gastric acid RELATED DISORDERS 中和胃酸;

Indication	For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Pharmacodynamics	Lansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours.
Mechanism of action	Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
Absorption	The absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%.
Volume of distribution	Not Available
Protein binding	97%
Metabolism	Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation. Enzyme Metabolite Reaction Km Vmax Cytochrome P450 3A4 Hydroxylansoprazole hydroxylation Cytochrome P450 3A4 Lansoprazole sulfone sulfoxidation Cytochrome P450 3A4 lansoprazole sulfide sulfoxidation 100 0 Cytochrome P450 2C9 Hydroxylansoprazole hydroxylation Cytochrome P450 2C19 Hydroxylansoprazole hydroxylation Cytochrome P450 2C19 5-hydroxylansoprazole 5-hydroxylation 0 0
Route of elimination	Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.
Half life	1.5 (± 1.0) hours
Clearance	Not Available
Toxicity	Symptoms of overdose include abdominal pain, nausea and diarrhea.
Affected organisms	Humans and other mammals
Pathways	Pathway Name SMPDB ID Lansoprazole Pathway SMP00227

Properties
State	solid
Melting point	178-182 oC
Experimental Properties	Property Value Source water solubility 0.97 mg/L PhysProp logP 1.9 PhysProp
Predicted Properties	Property Value Source water solubility 2.50e-01 g/l ALOGPS logP 2.84 ALOGPS logP 3.03 ChemAxon Molconvert logS -3.17 ALOGPS pKa 17.30 ChemAxon Molconvert hydrogen acceptor count 4 ChemAxon Molconvert hydrogen donor count 1 ChemAxon Molconvert polar surface area 67.87 ChemAxon Molconvert rotatable bond count 6 ChemAxon Molconvert refractivity 87.61 ChemAxon Molconvert polarizability 34.59 ChemAxon Molconvert

Drug	Interaction
Atazanavir	This gastric pH modifier decreases the levels/effects of atazanavir
Enoxacin	Lansoprazole may decrease the absorption of enoxacin.
Indinavir	Omeprazole decreases the absorption of indinavir
Itraconazole	The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole.
Ketoconazole	The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.
Sucralfate	Sucralfate decreases the effect of lansoprazole

• Avoid alcohol.
• Food reduces bioavailabilty, but this has very little clinical impact.
• Take 30-60 minutes before meals.